The contemporary treatment of angina is centred around improving coronary arterial flow and increasing perfusion of ischaemic myocardium. This is variably achieved with medication, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The coronary sinus reducer (CSR; Neovasc Inc., Richmond, BC, Canada) is the only therapy which attempts to improve angina by acting on the postcapillary myocardial circulation. Unlike PCI, which has an intuitive, well-described, extensively investigated mechanism, how the CSR affects angina is not well understood.
The CSR is an hourglass-shaped, balloon-mounted, wire-mesh device that reduces the coronary sinus lumen, after inflammation and fibrosis have caused ...
State of the Art on ViV-TAVI; Transseptal Punctures; Endovascular Closure and TF-TAVI; Percutaneous PVL Closure: Long-Term Outcomes; and more
October 20, 2021